Latest by Gay Men's Health Crisis

Promo Image

Women, Men and Microbicides

We've heard a lot about HIV entry inhibitors in 2003. The new injectable fusion blocker Fuzeon (T-20, enfuvirtide) is the first member of this new class of HIV drugs to hit the market, and several oral drugs intended to block HIV entry into cells at ...

Promo Image

HIV/AIDS and People With Disability

Reprinted from The Lancet, April 26, 2003

Although AIDS researchers have studied the disabling effects of HIV/AIDS on previously healthy people, little attention has been given to the risk of HIV/AIDS for individuals who have a physical, sensory, in...

Promo Image

Moving Forward With Integrative AIDS Research

The Foundation for Integrative AIDS Research (FIAR) is a not-for-profit organization formed in October, 2001, to sponsor and stimulate interest in clinical trials of herbal and nutritional treatments for people with HIV, AIDS and chronic hepatitis. T...

Promo Image

Reyataz Dosing Options Discussed

Atazanavir has been developed as a once-a-day (QD) protease inhibitor to treat HIV infection in combination with other antiretrovirals. Its approved dosage will be 400 mg QD, taken with food. The convenience of QD dosing is expected to enhance regime...

Promo Image

Notes on HIV Drugs in Development


On May 13, 2003, an FDA advisory committee met outside of Washington, D.C. to consider the approval of a new protease inhibitor, atazanavir (ATV). The drug was mostly well received by the committee; efficacy in treatment naive patients wa...

Promo Image

Gilead's Viread International Access Program

Last December Gilead Sciences announced a plan to make their nucleotide reverse transcriptase inhibitor Viread (tenofovir) available to clinics and treatment programs in the developing world at an affordable price. Joe Steele, the architect of Gilead...

Promo Image

Nevirapine-Based Fixed-Dose Combination Antiretrovirals in Resource-Limited Settings

Advisory panel members include Dr. Vijay Anthony Prabhu (Chennai, India), and Desmond Martin (President, Southern Africa HIV Clinicians Society); they both provide commentary in this article.

Fixed-dose combination antiretrovirals (FDC ARVs) are pro...

Promo Image

Showdown at the X4 Corral

For most people, HIV infection, if not treated, causes a long, slow decline in immune capacity to a point when they become susceptible to dangerous opportunistic infections. In some, this decline can happen within a few years; for a few, it hasn't ha...

Promo Image

HIV Pathogenesis Reports From the 10th Retrovirus Conference

The 10th Annual Retrovirus Conference held recently in Boston featured several presentations on novel ways to look at HIV pathogenesis (how the virus causes disease) and how the virus might evade attacks by each of the three main immune defense syste...

Promo Image

Testing HIV-Positive in New York City: 2001 HIV/AIDS Surveillance Report

HIV and AIDS in New York City: An Overview

As of March 31, 2002, 76,504 New Yorkers were diagnosed and known to be living with HIV or AIDS.

An estimated 25,000 additional people are living with HIV but have not yet been diagnosed.

1.7% of blacks, ...